Published in Cancer Res on May 15, 2001
Neuroblastoma and MYCN. Cold Spring Harb Perspect Med (2013) 1.75
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs (2006) 1.05
Peroxisome-proliferator-activated-receptor gamma (PPARgamma) independent induction of CD36 in THP-1 monocytes by retinoic acid. Immunology (2002) 0.90
Radioprotection by the histone deacetylase inhibitor phenylbutyrate. Radiat Environ Biophys (2011) 0.87
Open tubular columns containing the immobilized ligand binding domain of peroxisome proliferator-activated receptors α and γ for dual agonists characterization by frontal affinity chromatography with mass spectrometry detection. J Chromatogr A (2013) 0.86
Interpreting clinical assays for histone deacetylase inhibitors. Cancer Manag Res (2011) 0.85
Effects of cryopreservation and phenylacetate on biological characters of adherent LAK cells from patients with hepatocellular carcinoma. World J Gastroenterol (2002) 0.83
Pleiotropic effects of glitazones: a double edge sword? Front Pharmacol (2011) 0.81
PPARgamma in Neuroblastoma. PPAR Res (2008) 0.80
Phenylbutyrate induces apoptosis and lipid accumulations via a peroxisome proliferator-activated receptor gamma-dependent pathway. NMR Biomed (2010) 0.79
PPAR Gamma in Neuroblastoma: The Translational Perspectives of Hypoglycemic Drugs. PPAR Res (2016) 0.77
Role of retinoids in the prevention and treatment of colorectal cancer. World J Gastrointest Oncol (2015) 0.76
Troglitazone Enhances the Apoptotic Response of DLD-1 Colon Cancer Cells to Photodynamic Therapy. Yonsei Med J (2016) 0.76
CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells. Front Mol Neurosci (2017) 0.75
Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst (1982) 1.96
Effects of retinoic acid (RA) on the growth and phenotypic expression of several human neuroblastoma cell lines. Exp Cell Res (1983) 1.53
Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells. Cancer Res (1995) 1.45
Potassium channels mediate killing by human natural killer cells. Proc Natl Acad Sci U S A (1986) 1.41
Human neuroblastoma cell lines as models for the in vitro study of neoplastic and neuronal cell differentiation. Environ Health Perspect (1989) 1.37
Complementary homeo protein gradients in developing limb buds. Genes Dev (1989) 1.11
K channels are expressed early in human T-cell development. Proc Natl Acad Sci U S A (1986) 1.04
Specific high-affinity binding and biologic action of retinoic acid in human neuroblastoma cell lines. Proc Natl Acad Sci U S A (1983) 0.99
Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells. Clin Cancer Res (2001) 0.99
Regulation of acetylcholinesterase activity by retinoic acid in a human neuroblastoma cell line. Exp Cell Res (1984) 0.96
Modulation of N-myc expression alters the invasiveness of neuroblastoma. Clin Exp Metastasis (1997) 0.96
In vitro production of human antibody to a tumour-associated foetal antigen. Br J Cancer (1981) 0.93
Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission. J Clin Invest (1996) 0.93
Neuroblastoma: clinical perspectives, monoclonal antibodies, and retinoic acid. Ann Intern Med (1982) 0.92
RU486-induced growth inhibition of human endometrial cells. Fertil Steril (2000) 0.92
Interleukin 2 and stimulator lymphoblastoid cells will induce human thymocytes to bind and kill K562 targets. J Exp Med (1982) 0.91
Inhibition of N-myc expression and induction of apoptosis by iron chelation in human neuroblastoma cells. Cancer Res (2001) 0.91
Retinoic acid induces the differentiation of B cell hybridomas from patients with common variable immunodeficiency. J Exp Med (1988) 0.90
Retinoids increase perinatal spinal cord neuronal survival and astroglial differentiation. Int J Dev Neurosci (1990) 0.89
B cells from a distinct subset of patients with common variable immunodeficiency (CVID) have increased CD95 (Apo-1/fas), diminished CD38 expression, and undergo enhanced apoptosis. Clin Exp Immunol (1995) 0.89
Retinoic acid-induced differentiation of human neuroblastoma: a cell variant system showing two distinct responses. Exp Cell Biol (1986) 0.89
Oncofoetal antigen I: a target for immune cytolysis of human cancer. Br J Cancer (1979) 0.89
Human medullary thyroid carcinoma. Initial characterization and in vitro differentiation of two new cell lines. Arch Otolaryngol Head Neck Surg (1989) 0.89
Retinoic acid treatment of human neuroblastoma cells is associated with decreased N-myc expression. Biochem Biophys Res Commun (1985) 0.88
Inhibition of estrogen-dependent breast cell responses with phenylacetate. Int J Cancer (2001) 0.87
Immunological aspects of retinoids in humans. III. Effects of retinoic acid on the natural killing of tumor cells. J Biol Response Mod (1985) 0.86
Effects of retinoic acid on the in vivo growth of human neuroblastoma cells. Cancer Lett (1990) 0.85
Immunological aspects of retinoids in humans. II. Retinoic acid enhances induction of hemolytic plaque-forming cells. Cell Immunol (1984) 0.85
Potassium channels in human NK cells are involved in discrete stages of the killing process. J Immunol (1986) 0.85
Identification and quantitation of intracellular retinol and retinoic acid binding proteins in cultured cells. Biochim Biophys Acta (1984) 0.84
Antiproliferative effect of the garlic compound S-allyl cysteine on human neuroblastoma cells in vitro. Cancer Lett (1992) 0.84
Retinoic acid blocks potassium channels in human lymphocytes. Biochem Biophys Res Commun (1986) 0.84
B cells from subjects with CVI can be driven to Ig production in response to CD40 stimulation. Cell Immunol (1992) 0.84
Lymphocyte surface markers and cytotoxicity following cryopreservation. J Immunol Methods (1980) 0.84
Retinoic acid inhibits Ca2+ currents and cell proliferation in a B-lymphocyte cell line. J Cell Physiol (1988) 0.83
Augmentation of human thymocyte proliferative responses by retinoic acid. Exp Cell Biol (1981) 0.83
Retinoic acid synthesis in normal and Alzheimer diseased brain and human neural cells. Mol Chem Neuropathol (1997) 0.83
Ultrastructural features of a human neuroblastoma cell line treated with retinoic acid. Neuroscience (1985) 0.82
Sodium currents during differentiation in a human neuroblastoma cell line. J Gen Physiol (1991) 0.82
Differential susceptibilities of spinal cord neurons to retinoic acid-induced survival and differentiation. Dev Biol (1991) 0.82
Long-term administration of 13-cis retinoic acid in common variable immunodeficiency: circulating interleukin-6 levels, B-cell surface molecule display, and in vitro and in vivo B-cell antibody production. Immunology (1993) 0.82
Retinoic acid suppresses interleukin-6 production in human endometrial cells. Fertil Steril (2000) 0.82
Effects of interferon-gamma and its interaction with retinoic acid on human neuroblastoma differentiation. Int J Cancer (1991) 0.81
Morphologic conversion of a neuroblastoma-derived cell line by E6-mediated p53 degradation. Cell Growth Differ (2001) 0.81
In vitro and in vivo effects of easily administered, low-toxic retinoid and phenylacetate compounds on human neuroblastoma cells. Br J Cancer (2003) 0.81
Cell type-specific activity of the N-myc promoter in human neuroblastoma cells is mediated by a downstream silencer. Oncogene (1995) 0.81
Properties of human neuroblastoma cells following induction by retinoic acid. Prog Clin Biol Res (1985) 0.80
Immunological aspects of retinoids in humans. I. Analysis of retinoic acid enhancement of thymocyte responses to PHA. Cell Immunol (1984) 0.79
Retinoic acid up-regulates nuclear retinoic acid receptor-alpha expression in human neuroblastoma cells. Int J Cancer (1994) 0.79
13-cis retinoic acid enhances in vivo B-lymphocyte differentiation in patients with common variable immunodeficiency. J Allergy Clin Immunol (1991) 0.78
Pharmacokinetics of chronically administered all-trans-retinoyl-beta-glucuronide in mice. Biochim Biophys Acta (2000) 0.77
Interferon-gamma and retinoic acid down-regulate N-myc in neuroblastoma through complementary mechanisms of action. Cancer Lett (1997) 0.77
Transcriptional regulation by retinoic acid of interleukin-2 alpha receptors in human B cells. Immunology (1994) 0.77
Modulation of intracellular cyclic adenosine monophosphate levels and the differentiation response of human neuroblastoma cells. Cancer Res (1990) 0.77
Differentiating effects of 1,25-dihydroxycholecalciferol (D3) on LA-N-5 human neuroblastoma cells and its synergy with retinoic acid. J Pediatr Hematol Oncol (1995) 0.76
Transcriptional upregulation of retinoic acid receptor beta (RAR beta) expression by phenylacetate in human neuroblastoma cells. Exp Cell Res (1998) 0.76
Saturation analysis of cellular retinoid binding proteins: application to retinoic acid resistant human neuroblastoma cells and to human tumors. Biochem Cell Biol (1987) 0.76
Increased in vivo mitogenicity of anti-TCR/CD3 monoclonal antibody through reduced interaction with Fcgamma receptors. Immunol Lett (2001) 0.76
Enhanced potency of 9-cis versus all-trans-retinoic acid to induce the differentiation of human neuroblastoma cells. Differentiation (1995) 0.75
Failure to detect killer cell activity in rabbits. Infect Immun (1982) 0.75
Vitamin D3 analogs inhibit growth and induce differentiation in LA-N-5 human neuroblastoma cells. Clin Exp Metastasis (1996) 0.75
Dual action of pancuronium on succinylcholine block. Can Anaesth Soc J (1977) 0.75
Phagocytic and Fc receptor functions of alveolar macrophages in cata following ingestion of hexachlorobenzene. Vet Hum Toxicol (1979) 0.75
Human monoclonal antibody to a neuroectodermal tumor antigen (OFA-I-2). Ann N Y Acad Sci (1983) 0.75
Social work in pediatric oncology: a family needs assessment. Soc Work Health Care (1995) 0.75
Neuraminidase-augmented anticarcinoembryonic antigen (CEA)-complement lysis of human colon tumor cells: lack of correlation with anti-CEA-mediated K-cell lysis and iodine-125 binding. J Natl Cancer Inst (1979) 0.75